Summary
This is study is treating low tumor burden follicular lymphoma, a type of slow-growing (indolent) blood cancer with a minimal amount of disease present in the body. The purpose of this study is to compare the usual treatment (rituximab) to using the study drug mosunetuzumab.
Description
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.